持续释放溶解微针的制造和特征评估,具有舒缓皮肤功能的功能
Yuting Yang1,2, Tingting Zhang1,2, Yan Zhang1,2
1Department of Clinical Laboratory Medicine, Shandong Medicine and Health Key Laboratory of Laboratory Medicine, The First Affiliated Hospital of Shandong First Medical University & Shandong Provincial Qianfoshan Hospital, Jinan, 250000, China.
Drug delivery and translational research
|February 20, 2026
概括
这项研究开发了使用氨酸,基乙纤维素和多重胺酸的舒缓溶解微针 (DMN). 优化的DMN证明了有效的皮肤透,快速溶解和皮肤修复,减少刺激,提高药物输送.
科学领域:
- 生物材料科学 生物材料科学
- 药物输送系统 药物输送系统
- 皮肤病学 皮肤病学
背景情况:
- 微针 (MNs) 为药物输送提供了一个有希望的途径.
- 溶解微针 (DMN) 由于其可生物降解性和低生物危害性而受到青.
- 多发性瘤的一个关键挑战是皮肤刺激,需要改进配方.
研究的目的:
- 开发新的舒缓和持续释放的DMN来缓解药物递送期间的皮肤刺激.
- 优化DMN配方使用具有固有的皮肤修复性质的生物相容材料.
- 评估制造的DMN的机械性能,皮肤透,溶解行为和皮肤修复效率.
主要方法:
- 使用氨酸 (HA-Na),基乙烯纤维素 (HEC) 和γ-多聚胺酸 (γ-PGA) 制造DMN.
- 通过直角实验优化DMN配方,评估形态和机械强度.
- 对皮肤 (猪皮和模拟皮肤) 透,压缩抗性和体外/体内溶解的最佳DMN的表征.
- 通过对小鼠的体内实验评估皮肤修复功能,对红斑和的监测.
主要成果:
- 最佳的DMN配方被确定为13%的HA-Na,7%的HEC和5%的γ-PGA,在30°C制造3小时.
- 制造的DMN表现出结构完整性,利的尖端,均的阵列和高达20N的机械强度.
- 在猪和模拟皮肤模型上以2N的力成功穿透皮肤.
- 在小鼠皮肤中的体内溶解在1小时内完成,表明持续释放的潜力.
- 用5%γ-PGA的DMN在小鼠中没有表现出红斑或,针孔在5分钟内消失,表明皮肤快速修复.
结论:
- 开发出来的DMN具有镇静,持续释放和皮肤修复的特性.
- 这些优化的DMN显示出在药物输送应用中减少皮肤刺激的潜力.
- 未来的研究应该专注于药物加载和通过皮肤释放的性能,以实现实际的药物输送.
相关概念视频
01:18Transdermal Drug Delivery Systems
46
Transdermal drug delivery systems (TDDS) enable the controlled release of drugs across the skin into systemic circulation. They are particularly advantageous for drugs with short half-lives or narrow therapeutic indices, as they maintain consistent plasma concentrations and reduce the risk of subtherapeutic or toxic levels.TDDS are categorized into monolithic, reservoir, and mixed systems. Monolithic systems embed the drug in a polymer matrix, where diffusion governs release. Reservoir systems...
46
01:11Oral Drug Delivery Systems: Delayed-Release Systems
44
Delayed-release drug delivery systems are specialized pharmaceutical formulations designed to postpone the release of active compounds until the drug reaches a specific region of the gastrointestinal (GI) tract, typically the intestine. These systems are essential for drugs that may cause gastric irritation, are unstable in acidic environments, or need to exert therapeutic effects locally in the intestinal or colonic regions.The core feature of delayed-release systems is the use of enteric...
44
01:30Modified-Release Drug Delivery Systems: Stimuli-Activated
32
Stimuli-activated drug delivery systems are designed to release drugs in response to specific physical, chemical, or biological stimuli. These systems often utilize hydrogels—three-dimensional, hydrophilic polymer networks capable of swelling in aqueous environments and retaining significant fluid volumes. Upon exposure to particular stimuli, these hydrogels undergo structural transitions that allow the embedded drug to be released. Due to this adaptive behavior, such systems are also...
32
01:23Factors Affecting Dissolution: Particle Size and Effective Surface Area
1.8K
Dissolution kinetics, an essential aspect of oral drug delivery, is significantly influenced by the drug's particle size. According to the Noyes-Whitney dissolution model, the dissolution rate correlates directly with the drug's surface area. The larger the surface area, the higher the drug's solubility in water, leading to a faster drug dissolution rate. Reducing particle size increases the effective surface area, enhancing the dissolution process. Micronization and nanosizing are...
1.8K
01:23Ophthalmic Drug Delivery Systems
61
Ophthalmic drug delivery faces major limitations due to poor absorption across the corneal membrane. This process is primarily driven by diffusion and is influenced by two main factors: the physicochemical properties of the drug and tear drainage. Most ophthalmic drugs, such as pilocarpine, epinephrine, atropine, and local anesthetics, are weak bases. They are typically formulated at an acidic pH to enhance chemical stability. However, this leads to high ionization, reducing their ability to...
61